ADCendo will develop a single oncology therapy combining antibodies with cytotoxic drugs used during chemotherapy.
ADCendo, a Denmark-based cancer treatment developer has signed a licensing agreement with University of Copenhagen and local government administration Capital Region of Denmark for potential treatments for bone, connective tissue and brain cancers.
Founded in July 2017, ADCendo hopes to develop antibody-drug conjugates – a compound connecting immune system antibodies, which target bacteria and viruses, with the cytotoxic compounds often used to kill cells during chemotherapy.
The therapy would work via the uParap receptor, which plays a role in wearing…
